Longeveron Inc

Explore how Longeveron’s new Japanese MSC potency‑assay patent and FDA Type C meeting pave the way for its HLHS therapy, Laromestrocel, to accelerate regulatory approval and market expansion.

Longeveron Inc. has appointed Than Powell as Chief Business Officer and announced significant progress in its clinical trials, including completion of enrollment in a pivotal Phase 2b trial for its HLHS treatment.

Longeveron Inc. is a clinical-stage biotech company pioneering cellular therapies to address aging-related and life-threatening conditions, with a promising future despite recent market fluctuations.